公开(公告)号：US09655865B2

公开(公告)日：2017-05-23

申请号：US12154907

申请日：2008-05-28

申请人： Anthony H. Cincotta

发明人： Anthony H. Cincotta

IPC分类号： A01N43/42 ,  A61K31/44 ,  A61K31/00 ,  A61K31/48 ,  A61K45/06

CPC分类号： A61K38/185 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/16 ,  A61K31/165 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4188 ,  A61K31/428 ,  A61K31/44 ,  A61K31/4458 ,  A61K31/46 ,  A61K31/473 ,  A61K31/48 ,  A61K31/495 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient.In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier.

公开(公告)号：US08741918B2

公开(公告)日：2014-06-03

申请号：US12144620

申请日：2008-06-23

申请人： Anthony H. Cincotta

发明人： Anthony H. Cincotta

IPC分类号： A01N43/42 ,  A01N43/58 ,  A01N43/60 ,  A61K31/44 ,  A61K31/50 ,  A61K31/495

CPC分类号： A61K31/4985 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/209 ,  A61K9/7007 ,  A61K31/00 ,  A61K31/135 ,  A61K31/485 ,  A61K31/55 ,  A61K45/06 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

摘要： This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

摘要翻译： 本发明涉及用于肠胃外给药的稳定的药物组合物，其包含可用于治疗代谢紊乱或其关键要素的多巴胺激动剂和外周作用剂。 肠胃外剂型显示长期稳定的保质期和明显的药代动力学。

公开(公告)号：US20110195971A1

公开(公告)日：2011-08-11

申请号：US13066280

申请日：2011-04-11

申请人： Anthony H. Cincotta

发明人： Anthony H. Cincotta

IPC分类号： A61K31/4985 ,  A61P9/00 ,  A61P3/00 ,  A61P3/10 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  G01N30/02

CPC分类号： A61K31/498 ,  G01N33/6896 ,  G01N33/9413 ,  G01N2333/52 ,  Y10S436/815 ,  Y10T436/145555 ,  Y10T436/173845

摘要： The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or said patient has hypertriglyceridemai and/or hypertension . The present invention is also directed to treating identified patients with dopamine agonist therapy.

摘要翻译： 本发明涉及一种通过多巴胺激动剂治疗来鉴定待治疗患者的方法，包括以下步骤：从去甲肾上腺素（NE），去甲肾上腺素代谢物（NE代谢物），多巴胺，多巴胺代谢物的浓度分析来自所述患者的血浆或尿样品 （a）NE代谢产物，（b）NE / NE代谢产物：多巴胺/多巴胺代谢产物，（c）NE和5-羟色胺，（d）NE / NE代谢产物和 5-羟色胺，（e）NE和5-羟色胺代谢物，（f）NE / NE代谢物和5-羟色胺代谢物，或（g）NE比正常水平高大约30％ 或多巴胺/多巴胺代谢物低于正常值的约30％ 或所述患者具有高甘油三酯和/或高血压。 本发明还涉及治疗多巴胺激动剂治疗的鉴定患者。

公开(公告)号：US6004972A

公开(公告)日：1999-12-21

申请号：US103105

申请日：1998-06-23

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/06 ,  G01N33/74 ,  A61K31/44

CPC分类号： G01N33/74 ,  A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  Y10S514/866

摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.

摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期每日给药复位脑神经中枢的激素时间以产生长期效应。

公开(公告)号：US5866584A

公开(公告)日：1999-02-02

申请号：US465818

申请日：1995-06-06

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/496 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61P3/08 ,  A61P3/10 ,  C07D457/00 ,  C07D457/04 ,  G01N33/74 ,  A61K31/44

CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/866

摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term, daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.

摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期内，每日给药复位脑神经中枢的激素时间以产生长期效果。

公开(公告)号：US5854255A

公开(公告)日：1998-12-29

申请号：US843760

申请日：1997-04-21

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/496 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61P3/06 ,  A61P3/08 ,  A61P3/10 ,  C07D457/00 ,  C07D457/04 ,  G01N33/74 ,  A61K31/44 ,  A61K31/495

CPC分类号： G01N33/74 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  Y10S514/866 ,  Y10S514/909

摘要： A therapeutic package for dispensing to, or for use in dispensing to, a vertebrate being treated for a metabolic condition selected from the group consisting of obesity, insulin resistance, hyperinsulinemia, and hyperglycemia comprising one or more unit doses of bromocriptine and labeling directing the use of the package in the treatment of the metabolic condition in a dosage regimen under which the delivery of the bromocriptine is confined to the period during the day near the time of day at which the serum prolactin concentration of a lean, insulin sensitive vertebrate of the same sex is low, and further directing the use of said package in conjunction with the concomitant administration to the vertebrate of one or more unit doses providing a therapeutically effective amount of a prolactin stimulator in a dosage regimen under which the delivery of the prolactin stimulator is confined to the period during the day after the time at which the serum prolactin concentration of a lean, insulin-sensitive vertebrate of the same sex reaches its lowest point and prior to the time of day when the prolactin concentration rises to a peak in lean, insulin-sensitive vertebrates of the same sex.

摘要翻译： 一种用于分配给或用于分配给被选择为选自肥胖症，胰岛素抵抗，高胰岛素血症和高血糖的代谢疾病的脊椎动物的治疗包，其包含一个或多个单位剂量的溴隐亭和指示使用的标记 该药物治疗代谢状况的剂量方案，其中溴隐亭的递送被限制在白天接近白天的贫血，胰岛素敏感性脊椎动物的血清催乳素浓度的同一时间段 性别低，并且进一步将所述包装的使用与所述脊椎动物联合给予脊椎动物一种或多种单位剂量，在剂量方案中提供治疗有效量的催乳素刺激剂，在该方案中，催乳激素刺激剂的输送被限制 到血清催乳素浓度的一段时间之后的一天中， 相同性别的ulin敏感脊椎动物达到其最低点，并且在同一性别的瘦，胰岛素敏感的脊椎动物中的催乳素浓度上升到峰值之前的时间之前。

公开(公告)号：US5744477A

公开(公告)日：1998-04-28

申请号：US178569

申请日：1994-01-07

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： C07D519/02 ,  A61K31/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  A61P43/00 ,  G01N33/74

CPC分类号： A61K31/4985 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/866 ,  Y10S514/884 ,  Y10S514/909

摘要： The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subject of a prolactin inhibitor. Additionally, the present invention is directed to an improvement in a method for altering and/or resetting prolactin profiles (and thereby controlling one or more metabolic disorders such as obesity, excessive body fat, hyperlipidemia, hyperlipoproteinemia, hyperglycemia, hypercholesterolemia, hyperinsulinemia, insulin resistance, glucose intolerance, and Type II diabetes) comprising administration to a subject in need of such treatment of a prolactin inhibitor at a predetermined time or times during a 24-hour period in combination with a (preferably moderate) reduction of the caloric intake of said subject.

摘要翻译： 本发明涉及一种重量和/或体脂肪减少方法的改进，包括需要这种治疗的受试者的热量摄入减少（优选中等），与给予所述受试者的催乳素抑制剂组合 。 此外，本发明涉及一种用于改变和/或重置催乳素谱（从而控制一种或多种代谢性疾病如肥胖，身体过量脂肪，高脂血症，高脂蛋白血症，高血糖症，高胆固醇血症，高胰岛素血症，胰岛素抵抗）的方法的改进 ，葡萄糖不耐受和II型糖尿病），其包括在24小时内预定时间或时间对需要这种治疗催乳激素抑制剂的受试者施用，与所述的 学科。

公开(公告)号：US5716962A

公开(公告)日：1998-02-10

申请号：US465820

申请日：1995-06-06

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/06 ,  G01N33/74 ,  A61K31/44

CPC分类号： G01N33/74 ,  A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  Y10S514/866

摘要： A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.

摘要翻译： 长期改变和调节脂质和碳水化合物代谢的过程 - 通常通过给药（即，通过给药（例如，通过给药）而减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过口服，舌下或本体给药）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一天的有限时间内取决于相似物种的胰岛素抵抗和胰岛素敏感成员的正常昼夜节律。 胰岛素抵抗和高胰岛素血症和高血糖或两者都可以通过这种治疗长期控制在人类中，因为短期每日给药复位脑神经中枢的激素时间以产生长期效应。

公开(公告)号：US5716932A

公开(公告)日：1998-02-10

申请号：US450917

申请日：1995-05-26

申请人： Albert H. Meier ,  Anthony H. Cincotta

发明人： Albert H. Meier ,  Anthony H. Cincotta

IPC分类号： A61K31/00 ,  A61K31/221 ,  A61K31/352 ,  A61K31/475 ,  A61K31/5513 ,  A61K38/22 ,  A61K45/06 ,  G01N33/74 ,  C07K14/64 ,  A61K38/00 ,  C07K9/00

CPC分类号： A61K31/4985 ,  A61K31/00 ,  A61K31/221 ,  A61K31/352 ,  A61K31/475 ,  A61K31/5513 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74

摘要： A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.

公开(公告)号：US5696128A

公开(公告)日：1997-12-09

申请号：US271881

申请日：1994-07-07

申请人： Anthony H. Cincotta ,  Albert H. Meier

发明人： Anthony H. Cincotta ,  Albert H. Meier

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/166 ,  A61K31/40 ,  A61K31/405 ,  A61K31/415 ,  A61K31/42 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/565 ,  A61K38/22 ,  A61K45/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A01N43/42 ,  A61K31/44

CPC分类号： A61K38/225 ,  A61K31/00 ,  A61K31/137 ,  A61K31/166 ,  A61K31/40 ,  A61K31/405 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/5415 ,  A61K38/2257 ,  A61K45/06

摘要： Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.

摘要翻译： 公开了用于整流或改善哺乳动物免疫系统的异常反应的方法。 还公开了用于修饰哺乳动物免疫系统的正常反应的方法。 进一步公开的是通过在哺乳动物的异常催乳素特征的修改中在预定时间或24小时期间向哺乳动物施用催乳素还原剂和/或增强剂来实现上述方法，使得其接近或符合 对于同一物种的年轻健康哺乳动物（或由这些个体产生的标准概况）的催乳素特征。 此外，公开了在哺乳动物中上调或增加免疫应答的方法。